title: Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
abstract: Brexpiprazole has previously demonstrated efficacy in acute schizophrenia trials. The objective of this trial was to assess the efficacy, safety, and tolerability of maintenance treatment with brexpiprazole in adults with schizophrenia.
  
  
  
  Patients with an acute exacerbation of psychotic symptoms were converted to brexpiprazole (1-4mg/d) over 1 to 4 weeks and entered a single-blind stabilization phase. Those patients who met stability criteria for 12 weeks were randomized 1:1 to double-blind maintenance treatment with either brexpiprazole (at their stabilization dose) or placebo for up to 52 weeks. The primary efficacy endpoint was the time from randomization to impending relapse. Safety and tolerability were also assessed.
  
  
  
  A total of 524 patients were enrolled, 202 of whom were stabilized on brexpiprazole and randomized to brexpiprazole (n=97) or placebo (n=105). Efficacy was demonstrated at a prespecified interim analysis (conducted after 45 events), and so the trial was terminated early. The final analysis showed that time to impending relapse was statistically significantly delayed with brexpiprazole treatment compared with placebo (P<.0001, log-rank test). The hazard ratio for the final analysis was 0.292 (95% confidence interval: 0.156, 0.548); mean dose at last visit, 3.6mg. The proportion of patients meeting the criteria for impending relapse was 13.5% with brexpiprazole and 38.5% with placebo (P<.0001). During the maintenance phase, the incidence of adverse events was comparable to placebo.
  
  
  
  or patients with schizophrenia already stabilized on brexpiprazole, maintenance treatment with brexpiprazole was efficacious, with a favorable safety profile.
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: W Wolfgang
authors: WW
authors: Fleischhacker
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Mary
authors: M
authors: Hobart
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: John
authors: J
authors: Ouyang
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Andy
authors: A
authors: Forbes
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Stephanie
authors: S
authors: Pfister
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Robert D
authors: RD
authors: McQuade
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: William H
authors: WH
authors: Carson
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Raymond
authors: R
authors: Sanchez
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Margareta
authors: M
authors: Nyilas
authors: Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria; Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA; H. Lundbeck A/S, Valby, Denmark.
authors: Emmanuelle
authors: E
authors: Weiller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D015363:Quinolones; D013876:Thiophenes; C000591922:brexpiprazole
keywords: brexpiprazole; maintenance; relapse; schizophrenia; stabilization